AOP Orphan Pharmaceuticals Aktiengesellschaft
AOP Orphan Pharmaceuticals Aktiengesellschaft
Contact:
AOP
Phone: +43 503 72 44 24
E-Mail: olena.weissenbacher@aoporphan.com
KEYWORDS:
  • Ropeginterferon alfa-2b
  • European Commission (EC)
  • Polycythaemia vera (PV)
  • BESREMi®
  • EU Marketing Authorization
  • AOP Orphan Pharmaceuticals AG
Download Photos
AOP Orphan Pharmaceuticals Aktiengesellschaft (13 releases)

* BESREMi® is approved as first-line monotherapy in adults for the treatment of Polycythaemia vera (PV) without symptomatic splenomegaly (1) [more]

AOP Orphan announces positive CHMP opinion for Ropeginterferon alfa-2b/BESREMi®
2018-12-17, pts20181217010 Science/Technology, Health/Medicine
AOP Orphan announces positive CHMP opinion for Ropeginterferon alfa-2b/BESREMi®
2018-12-17, pts20181217008 Science/Technology, Health/Medicine
AOP Orphan announces three-year results on Ropeginterferon alfa-2b in Polycythemia Vera at ASH
2018-12-03, pts20181203046 Health/Medicine, Products/Innovations
AOP Orphan and Bioprojet Pharma SAS entered a distribution agreement for Wakix®
2018-03-22, pts20180322023 Products/Innovations, Science/Technology
AOP Orphan announces two-year results on Ropeginterferon alfa-2bin PV
2017-12-10, pts20171210001 Health/Medicine, Science/Technology
AOP Orphan Pharmaceuticals AG to acquire Selisistat
2017-10-02, pts20171002022 Products/Innovations, Health/Medicine
AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in PV
2017-06-25, pts20170625010 Products/Innovations, Health/Medicine

1 2 Next »